Bisphosphonates for osteoporosis
Relevant BNF section: 6.6.2
One in three women and at least one in 12 men in the UK have osteoporosis, a condition which can lead to fractures, deformity, pain and disability, at a cost to the NHS of around £1.5 billion each year.1,2 Bisphosphonates offer a therapeutic option for preventing and treating osteoporosis. Here, we assess and compare the three bisphosphonates (alendronate, etidronate and ▼risedronate*) licensed for such use in the UK. We do not consider the four bisphosphonates (clodronate, pamidronate, tiludronate and ▼zoledronate) that are licensed in the UK only for the treatment of Paget's disease of bone and/or hypercalcaemia of malignancy.
This article has been cited by other articles:
-
(2008). Annual {blacktriangledown}zoledronic acid for osteoporosis. DTB
46: 93-96
[Abstract] [Full Text] -
Jones, D. G., Savage, R., Highton, J.
(2005). Synovitis induced by alendronic acid can present as acute carpal tunnel syndrome. BMJ
330: 74-74
[Full Text] -
Saad, F.
(2003). Bisphosphonates in Prostate Cancer: Where Are We and Where Should We Go?. JNCI J Natl Cancer Inst
95: 1262-1263
[Full Text]
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
